NasdaqGS:ZVRAPharmaceuticals
Assessing Zevra Therapeutics (ZVRA) Valuation After Its First Quarter 2026 Profit Turnaround
Zevra Therapeutics (ZVRA) drew fresh attention after reporting first quarter 2026 earnings, with sales of US$36.22 million and net income of US$37.89 million, compared with a net loss a year earlier.
See our latest analysis for Zevra Therapeutics.
The latest earnings headline has been met with strong buying interest, with the stock’s 1 day share price return of 6.03% helping extend a 34.89% year to date share price gain and a 1 year total shareholder return of 49.80%, which follows very large...